RT Journal Article
SR Electronic
T1 Deep learning for predicting COVID-19 malignant progression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.20.20037325
DO 10.1101/2020.03.20.20037325
A1 Fang, Cong
A1 Bai, Song
A1 Chen, Qianlan
A1 Zhou, Yu
A1 Xia, Liming
A1 Qin, Lixin
A1 Gong, Shi
A1 Xie, Xudong
A1 Zhou, Chunhua
A1 Tu, Dandan
A1 Zhang, Changzheng
A1 Liu, Xiaowu
A1 Chen, Weiwei
A1 Bai, Xiang
A1 Torr, Philip H.S.
YR 2020
UL http://medrxiv.org/content/early/2020/09/12/2020.03.20.20037325.abstract
AB As COVID-19 is highly infectious, many patients can simultaneously flood into hospitals for diagnosis and treatment, which has greatly challenged public medical systems. Treatment priority is often determined by the symptom severity based on first assessment. However, clinical observation suggests that some patients with mild symptoms may quickly deteriorate. Hence, it is crucial to identify patient early deterioration to optimize treatment strategy. To this end, we develop an early-warning system with deep learning techniques to predict COVID-19 malignant progression. Our method leverages clinical data and CT scans of outpatients and achieves an AUC of 0.920 in the single-center study and an average AUC of 0.874 in the multicenter study. Moreover, our model automatically identifies crucial indicators that contribute to the malignant progression, including Troponin, Brain natriuretic peptide, White cell count, Aspartate aminotransferase, Creatinine, and Hypersensitive C-reactive protein.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Key R&D Program of China (No. 2018YFB1004600), HUST COVID-19 Rapid Response Call (No. 2020kfyXGYJ093, No. 2020kfyXGYJ094), National Natural Science Foundation of China (No.61703049, No. 81401390).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author had full access to all data and the final responsibility to submit for publication.